Parse Biosciences, a QIAGEN Company, Launches FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis

Parse Biosciences, a QIAGEN company and the leading provider of scalable and accessible single-cell sequencing solutions, today announced the commercial availability of Evercode™ Whole Transcriptome ...
TMCnet

BostonGene RNA Transcriptome Profiling Reveals New ADC Targets in Advanced Solid Tumors

BostonGene, developer of the leading AI foundation model for tumor and immune biology, announced results from the FEASY study ...

Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month

Caris Life Sciences® (NASDAQ: CAI), a leading patient-centric, next-generation AI TechBio company and precision medicine ...
ascopubs.org

Costs and Benefits of Whole-Exome, Whole-Transcriptome Sequencing in Patients With Advanced Non–Small Cell Lung Cancer

Functional Characterization of Variants of Unknown Significance of Fibroblast Growth Factor Receptors 1-4 and Comparison With AI Model–Based Prediction An economic model was developed to estimate the ...
Baylor College of Medicine

Baylor researchers develop and validate clinical diagnostic RNA sequencing test

RNA sequencing has emerged as a powerful supplement to DNA sequencing for Mendelian disease diagnosis, but clinical translation of diagnostic RNA-seq has not been widely achieved. Researchers at ...

Caris Life Sciences (CAI) Expands AI Insights Portfolio With Signature to Predict Ovarian Cancer Platinum Resistance

Caris Life Sciences Inc. (NASDAQ:CAI) is one of the best NASDAQ stocks under $30 to buy. On March 16, Caris Life Sciences ...
Healthcare IT News

AI to power Singapore's next-gen cancer profiling test

A $4.7 million collaboration led by the National Cancer Centre Singapore will develop a clinical-grade test using AI and ...